BiographyDr. Farouc Jaffer graduated from Stanford University in 1990 with a B.S. in Mathematical and Computational Sciences, and received in M.D. and Ph.D. in Biophysics from the University of Pennsylvania of Medicine in 1996. He completed a residency in internal medicine at the Brigham and Women's Hospital followed by a fellowship in cardiovascular medicine and interventional cardiology at Massachusetts General Hospital. In 2003, he joined the Cardiology Division and CMIR as faculty.
He is an Associate Professor of Medicine at Harvard Medical School and an Attending Interventional Cardiologist at Massachusetts General Hospital. Dr. Jaffer is also a Principal Investigator in the MGH Cardiovascular Research Center where his experimental laboratory develops novel molecular imaging approaches to image inflammation in atherosclerosis and venous thrombosis. His goal is to develop new translatable imaging echnology that could help predict and prevent heart attacks and strokes.
Dr. Jaffer is the Medical Director of Coronary Artery Disease Program at Massachusetts General Hospital. He specializes in the interventional treatment of coronary artery disease.
Dr. Jaffer is also the Co-Director of the Chronic Total Occlusion (CTO) PCI Intervention Program at Massachusetts Gneral Hospital. This unique center offers interventional options to treat patients limited by angina from CTO arteries, the hardest subset of blockages in interventional cardiology. Many patients who were told no options were available have been successfully treated with CTO PCI strategies, and have marked reductions in angina, chest pain, and shortness of breath with exertion.
We are developing new approaches to image high-risk plaques (narrowings, blockages) that cause myocardial infarction (heart attacks). Imaging of high-risk ("vulnerable") coronary plaques could ultimately help prevent heart attacks from occurring.
Specifically, we are developing new intravascular optical (near-infrared fluorescence) imaging catheters to visualize inflammation in plaques. Inflammation is a key driver of plaque ruptures and heart attacks. Novel molecular imaging catheters are undergoing bench and experimental testing. Our goal is to translate these technologies to patients with coronary artery disease (CAD), with the goal of identifying inflamed high-rsk plaques. Eventually identifying these plaques may allow us to pre-emptively treat then prior to rupture and heart attack.
Jaffer FA, et al. Real-time Catheter Molecular Sensing of Inflammation in Proteolytically Active Atherosclerosis. Circulation 2008; 118:1802-9.
Calfon MA, Vinegoni C, Ntziachristos V, Jaffer FA. Intravascular Near-infrared Fluorescence Molecular Imaging of Atherosclerosis: Towards Coronary Arterial Visualization of Biologically High-Risk Plaques. Journal of Biomedical Optics (Jan. 14, 2010).
Sabatine MS, Jaffer FA, et al. A 32-Year-Old Woman, 3 Weeks Postpartum, with Substernal Chest Pain. New England Journal of Medicine 2010; 363:1164-1173.Please see weblink below for full publication details.
New treatment option allows some coronary artery patients to "bypass" bypass surgery. Interventional cardiologists at the Institute for Heart, Vascular and Stroke Care at Mass General offer a less-invasive treatment with quicker recovery.
Massachussets General Hospital offers a minimally invasive procedure to treat chronic total occlusions (CTOs).
A new device that combines two microimaging technologies can reveal both the detailed anatomy of arterial linings and biological activities that, in coronary arteries, could indicate the risk of heart attacks or the formation of clots in arterial stents.
Phone 2: 617-724-9353